A gene-based score for the risk stratification of stage IA lung adenocarcinoma

Yanlu Xiong,Yongfu Ma,Kun Liu,Jie Lei,Jinbo Zhao,Jianfei Zhu,Wenchen Wang,Miaomiao Wen,Xuejiao Wang,Ying Sun,Yabo Zhao,Yong Han,Tao Jiang,Yang Liu
DOI: https://doi.org/10.1186/s12931-023-02647-4
IF: 5.8
2024-01-04
Respiratory Research
Abstract:Abstract Objective We aim to molecularly stratify stage IA lung adenocarcinoma (LUAD) for precision medicine. Methods Twelve multi-institution datasets (837 cases of IA) were used to classify the high- and low-risk types (based on survival status within 5 years), and the biological differences were compared. Then, a gene-based classifying score (IA score) was trained, tested and validated by several machine learning methods. Furthermore, we estimated the significance of the IA score in the prognostic assessment, chemotherapy prediction and risk stratification of stage IA LUAD. We also developed an R package for the clinical application. The SEER database (15708 IA samples) and TCGA Pan-Cancer (1881 stage I samples) database were used to verify clinical significance. Results Compared with the low-risk group, the high-risk group of stage IA LUAD has obvious enrichment of the malignant pathway and more driver mutations and copy number variations. The effect of the IA score on the classification of high- and low-risk stage IA LUAD was much better than that of classical clinicopathological factors (training set: AUC = 0.9, validation set: AUC = 0.7). The IA score can significantly predict the prognosis of stage IA LUAD and has a prognostic effect for stage I pancancer. The IA score can effectively predict chemotherapy sensitivity and occult metastasis or invasion in stage IA LUAD. The R package IAExpSuv has a good risk probability prediction effect for both groups and single stages of IA LUAD. Conclusions The IA score can effectively stratify the risk of stage IA LUAD, offering good assistance in precision medicine.
respiratory system
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to conduct molecular - level risk stratification for stage IA lung adenocarcinoma (LUAD) in order to achieve precision medicine. Specifically, the authors aim to distinguish high - risk and low - risk subtypes in stage IA lung adenocarcinoma by establishing a gene - based classification score (IA score), thereby providing guidance for clinical treatment. This research is of great significance for avoiding over - treatment of low - risk patients and under - treatment of high - risk patients. ### Main research objectives: 1. **Molecular stratification**: Divide stage IA lung adenocarcinoma patients into high - risk and low - risk subtypes through molecular characteristics. 2. **Prognosis assessment**: Evaluate the effect of the IA score in predicting patient prognosis. 3. **Chemotherapy prediction**: Explore the application of the IA score in predicting chemotherapy sensitivity. 4. **Risk stratification**: Identify high - risk subgroups that may require more aggressive treatment (such as postoperative adjuvant chemotherapy). ### Research methods: - **Dataset integration**: Integrated 12 multi - institutional datasets, including a total of 837 stage IA lung adenocarcinoma patients. - **Batch effect correction**: Used three methods, z - scaling, removeBatchEffect and Combat, to remove batch effects. - **Biological difference analysis**: Compared the biological differences between high - risk and low - risk subtypes through gene set enrichment analysis (GSEA) and mutation analysis. - **Machine - learning modeling**: Used multiple machine - learning algorithms (such as k - nearest neighbor, naive Bayes, neural network, etc.) to establish and validate the IA score. - **Survival analysis**: Evaluated the prognostic value of the IA score through methods such as Kaplan - Meier curves and Cox regression analysis. - **Decision - curve analysis**: Evaluated the benefits of the IA score in clinical decision - making. ### Main findings: - **Biological differences**: The enrichment of malignant pathways is more significant in the high - risk subtype, and there are more driver mutations and copy number variations. - **Prognosis prediction**: The IA score performs better than traditional clinicopathological factors in distinguishing high - risk and low - risk subtypes (training set AUC = 0.9, validation set AUC = 0.7). - **Chemotherapy sensitivity**: The IA score can effectively predict chemotherapy sensitivity and occult metastasis or invasion. - **Clinical application**: Developed the R package IAExpSuv for clinical risk probability prediction. ### Conclusion: The IA score can effectively stratify the risk of stage IA lung adenocarcinoma and provides strong support for precision medicine. This research provides clinicians with new tools, which helps optimize treatment strategies and improve patients' survival rates and quality of life.